Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults
Status:
Completed
Trial end date:
2016-01-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of the norovirus bivalent virus-like
particle (VLP) vaccine for further development by assessing the rates of serious adverse
events (SAEs), unsolicited adverse events (AEs), solicited local and solicited systemic AEs,
Adverse Events of Special Interest (AESIs) and AEs leading to participant's withdrawal from
the trial.
Phase:
Phase 2
Details
Lead Sponsor:
Takeda
Treatments:
Aluminum Hydroxide Monophosphoryl lipid A Vaccines